Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) EPS (Weighted Average and Diluted) (2020 - 2025)

Seres Therapeutics' EPS (Weighted Average and Diluted) history spans 6 years, with the latest figure at $0.94 for Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 116.4% year-over-year to $0.94; the TTM value through Sep 2025 reached $16.29, up 204.42%, while the annual FY2024 figure was -$0.81, 45.64% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q3 2025 was $0.94 at Seres Therapeutics, up from -$2.27 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $13.87 in Q4 2024 and bottomed at -$5.73 in Q3 2024.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.53 (2021), against an average of -$0.1.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 1607.61% in 2024 against a maximum downside of 1690.62% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.53 in 2021, then skyrocketed by 113.21% to $0.07 in 2022, then tumbled by 1414.29% to -$0.92 in 2023, then surged by 1607.61% to $13.87 in 2024, then tumbled by 93.22% to $0.94 in 2025.
  • Per Business Quant, the three most recent readings for MCRB's EPS (Weighted Average and Diluted) are $0.94 (Q3 2025), -$2.27 (Q2 2025), and $3.75 (Q1 2025).